Profile data is unavailable for this security.
About the company
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
- Revenue in USD (TTM)0.00
- Net income in USD-29.98m
- Incorporated2021
- Employees41.00
- LocationCalidi Biotherapeutics Inc4475 Executive Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 794-9600
- Fax+1 (858) 794-9605
- Websitehttps://www.calidibio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plus Therapeutics Inc (USA) | 6.08m | -11.77m | 8.73m | 20.00 | -- | -- | -- | 1.43 | -3.19 | -3.19 | 1.67 | -1.13 | 0.5724 | -- | -- | 304,200.00 | -110.75 | -59.18 | -- | -133.04 | -- | -- | -193.49 | -470.45 | -- | -- | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 8.78m | 20.00 | -- | -- | -- | 675.58 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 9.34m | 389.00 | 0.0017 | 0.0002 | 1.01 | 0.1641 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
GlucoTrack Inc | 0.00 | -8.74m | 9.48m | 6.00 | -- | 24.61 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
Eterna Therapeutics Inc | 115.00k | -22.92m | 9.52m | 8.00 | -- | -- | -- | 82.80 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
Agile Therapeutics Inc | 21.50m | -7.79m | 9.67m | 19.00 | -- | -- | -- | 0.4498 | -3.65 | -3.65 | 6.98 | -1.51 | 1.63 | 2.90 | 5.42 | 1,131,316.00 | -59.25 | -94.24 | -- | -142.62 | 59.73 | -- | -36.26 | -513.50 | 0.3843 | -- | -- | -- | 80.02 | -- | 43.08 | -- | -- | -- |
Calidi Biotherapeutics Inc | 0.00 | -29.98m | 9.87m | 41.00 | -- | -- | -- | -- | -0.6765 | -0.6765 | 0.00 | -0.4079 | 0.00 | -- | -- | 0.00 | -382.78 | -- | -- | -- | -- | -- | -- | -- | -- | -27.45 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
Traws Pharma Inc | 226.00k | -18.16m | 10.12m | 16.00 | -- | 1.40 | -- | 44.77 | -0.8641 | -0.8641 | 0.0108 | 0.2853 | 0.0085 | -- | 12.91 | 14,125.00 | -68.21 | -63.43 | -104.99 | -85.72 | -- | -- | -8,033.63 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
Vaccinex Inc | 124.00k | -19.19m | 10.20m | 37.00 | -- | 7.19 | -- | 82.28 | -46.02 | -46.02 | 0.1685 | 1.68 | 0.0202 | -- | 0.0894 | 3,351.35 | -312.93 | -262.29 | -731.45 | -- | -- | -- | -15,472.58 | -4,257.17 | -- | -55.90 | 0.03 | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
Alaunos Therapeutics Inc | 6.00k | -26.77m | 10.41m | 1.00 | -- | 2.17 | -- | 1,734.69 | -1.67 | -1.67 | 0.0004 | 0.2996 | 0.0002 | -- | 12.00 | 6,000.00 | -97.94 | -74.83 | -147.22 | -89.57 | -- | -- | -446,233.30 | -10,508.06 | -- | -19.25 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
Longeveron Inc | 978.00k | -21.62m | 10.48m | 23.00 | -- | 1.37 | -- | 10.71 | -9.58 | -9.58 | 0.4297 | 1.21 | 0.0621 | -- | 7.14 | 42,521.74 | -132.19 | -63.15 | -184.16 | -75.68 | 48.47 | 33.70 | -2,129.24 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
ELEVAI Labs Inc | 2.18m | -4.62m | 10.81m | 18.00 | -- | 3.99 | -- | 4.95 | -0.2665 | -0.2665 | 0.126 | 0.1435 | -- | -- | -- | 121,351.70 | -- | -- | -- | -- | 67.84 | -- | -211.42 | -- | 1.80 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
Organovo Holdings Inc | 109.00k | -14.67m | 10.98m | 12.00 | -- | 2.14 | -- | 100.73 | -1.62 | -1.62 | 0.0119 | 0.3573 | 0.0082 | -- | 1.18 | 5,450.00 | -110.05 | -54.25 | -138.86 | -58.42 | -- | -- | -13,459.63 | -1,890.16 | 1.96 | -- | 0.00 | -- | -70.54 | -48.78 | 15.00 | -- | -11.87 | -- |
Holder | Shares | % Held |
---|---|---|
Red Wave Investments LLCas of 31 Mar 2024 | 644.60k | 1.27% |
Cable Car Capital LLCas of 31 Mar 2024 | 472.76k | 0.93% |
Meteora Capital LLCas of 31 Mar 2024 | 249.81k | 0.49% |
Spectrum Asset Management, Inc. (California)as of 31 Mar 2024 | 166.49k | 0.33% |
Finepoint Capital LPas of 31 Mar 2024 | 125.00k | 0.25% |
Polar Asset Management Partners, Inc.as of 31 Mar 2024 | 125.00k | 0.25% |
Geode Capital Management LLCas of 31 Mar 2024 | 107.11k | 0.21% |
Governors Lane LPas of 31 Mar 2024 | 94.70k | 0.19% |
Driehaus Capital Management LLCas of 31 Mar 2024 | 94.70k | 0.19% |
CPR Investments, Inc.as of 31 Mar 2024 | 70.00k | 0.14% |